242 related articles for article (PubMed ID: 25380215)
1. Synthesis and evaluation of protein arginine N-methyltransferase inhibitors designed to simultaneously occupy both substrate binding sites.
van Haren M; van Ufford LQ; Moret EE; Martin NI
Org Biomol Chem; 2015 Jan; 13(2):549-60. PubMed ID: 25380215
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1.
Dowden J; Pike RA; Parry RV; Hong W; Muhsen UA; Ward SG
Org Biomol Chem; 2011 Oct; 9(22):7814-21. PubMed ID: 21952734
[TBL] [Abstract][Full Text] [Related]
3. Peptidic transition state analogues as PRMT inhibitors.
Zhang Y; van Haren MJ; Martin NI
Methods; 2020 Mar; 175():24-29. PubMed ID: 31421210
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level.
Tewary SK; Zheng YG; Ho MC
Cell Mol Life Sci; 2019 Aug; 76(15):2917-2932. PubMed ID: 31123777
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor.
Ferreira de Freitas R; Eram MS; Szewczyk MM; Steuber H; Smil D; Wu H; Li F; Senisterra G; Dong A; Brown PJ; Hitchcock M; Moosmayer D; Stegmann CM; Egner U; Arrowsmith C; Barsyte-Lovejoy D; Vedadi M; Schapira M
J Med Chem; 2016 Feb; 59(3):1176-83. PubMed ID: 26824386
[TBL] [Abstract][Full Text] [Related]
6. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
[TBL] [Abstract][Full Text] [Related]
7. A patent review of arginine methyltransferase inhibitors (2010-2018).
Li X; Wang C; Jiang H; Luo C
Expert Opin Ther Pat; 2019 Feb; 29(2):97-114. PubMed ID: 30640571
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel PRMT1 inhibitors and investigation of their binding preferences using molecular modelling.
Yang H; Ouyang Y; Ma H; Cong H; Zhuang C; Lok WT; Wang Z; Zhu X; Sun Y; Hong W; Wang H
Bioorg Med Chem Lett; 2017 Oct; 27(20):4635-4642. PubMed ID: 28927791
[TBL] [Abstract][Full Text] [Related]
9. The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors.
Sun Y; Wang Z; Yang H; Zhu X; Wu H; Ma L; Xu F; Hong W; Wang H
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390828
[TBL] [Abstract][Full Text] [Related]
10. Nη-substituted arginyl peptide inhibitors of protein arginine N-methyltransferases.
Lakowski TM; 't Hart P; Ahern CA; Martin NI; Frankel A
ACS Chem Biol; 2010 Nov; 5(11):1053-63. PubMed ID: 20701328
[TBL] [Abstract][Full Text] [Related]
11. Small molecule regulators of protein arginine methyltransferases.
Cheng D; Yadav N; King RW; Swanson MS; Weinstein EJ; Bedford MT
J Biol Chem; 2004 Jun; 279(23):23892-9. PubMed ID: 15056663
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of carbocyanine dyes as PRMT inhibitors and imaging agents.
Sinha SH; Owens EA; Feng Y; Yang Y; Xie Y; Tu Y; Henary M; Zheng YG
Eur J Med Chem; 2012 Aug; 54():647-59. PubMed ID: 22749641
[TBL] [Abstract][Full Text] [Related]
13. In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1.
Osborne T; Roska RL; Rajski SR; Thompson PR
J Am Chem Soc; 2008 Apr; 130(14):4574-5. PubMed ID: 18338885
[TBL] [Abstract][Full Text] [Related]
14. Protein arginine N-methyltransferase substrate preferences for different nη-substituted arginyl peptides.
Thomas D; Koopmans T; Lakowski TM; Kreinin H; Vhuiyan MI; Sedlock SA; Bui JM; Martin NI; Frankel A
Chembiochem; 2014 Jul; 15(11):1607-13. PubMed ID: 25044481
[TBL] [Abstract][Full Text] [Related]
15. Biochemistry and regulation of the protein arginine methyltransferases (PRMTs).
Morales Y; Cáceres T; May K; Hevel JM
Arch Biochem Biophys; 2016 Jan; 590():138-152. PubMed ID: 26612103
[TBL] [Abstract][Full Text] [Related]
16. The C. elegans PRMT-3 possesses a type III protein arginine methyltransferase activity.
Takahashi Y; Daitoku H; Yokoyama A; Nakayama K; Kim JD; Fukamizu A
J Recept Signal Transduct Res; 2011 Apr; 31(2):168-72. PubMed ID: 21385054
[TBL] [Abstract][Full Text] [Related]
17. A Pan-Inhibitor for Protein Arginine Methyltransferase Family Enzymes.
Iyamu ID; Al-Hamashi AA; Huang R
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34201091
[TBL] [Abstract][Full Text] [Related]
18. Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential.
Krause CD; Yang ZH; Kim YS; Lee JH; Cook JR; Pestka S
Pharmacol Ther; 2007 Jan; 113(1):50-87. PubMed ID: 17005254
[TBL] [Abstract][Full Text] [Related]
19. Investigating the binding preferences of small molecule inhibitors of human protein arginine methyltransferase 1 using molecular modelling.
Hong W; Li J; Laughton CA; Yap LF; Paterson IC; Wang H
J Mol Graph Model; 2014 Jun; 51():193-202. PubMed ID: 24937176
[TBL] [Abstract][Full Text] [Related]
20. Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis.
Osborne TC; Obianyo O; Zhang X; Cheng X; Thompson PR
Biochemistry; 2007 Nov; 46(46):13370-81. PubMed ID: 17960915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
